Q3 2024 Medivir AB Earnings Call Transcript
Key Points
- Medivir AB (OSTO:MVIR) presented promising mature data at the ESMO Congress, showing a median time to progression of 10.9 months for their FSRS and Lenvima combination, significantly longer than current second-line treatments.
- The company announced a clinical trial collaboration with A I, which includes a supply agreement for Lenvima, reducing potential costs by $15 to $20 million.
- Medivir AB (OSTO:MVIR) retains full rights to their FSRS asset despite the collaboration, allowing flexibility for future partnerships or equity financing.
- The FSRS and Lenvima combination has shown a favorable safety profile, with stable liver function and minimal impact on platelets and neutrophils, enabling long-term treatment.
- There is a significant unmet need in second-line liver cancer treatment, and Medivir AB (OSTO:MVIR) is positioned to potentially be the first approved option in this space, targeting a market valued at over $2.5 billion by 2030.
- Medivir AB (OSTO:MVIR) reported an operating loss of SEK 46 million for Q3, higher than the previous year, due to ongoing clinical and CMC costs.
- The company is in need of additional capital to fund the upcoming phase 2B study, exploring various financing options including equity financing and partnerships.
- Despite the promising data, the competitive landscape in oncology remains challenging, with many ongoing studies in first-line liver cancer treatment.
- The growth of liver cancer incidence is increasing, driven by factors like obesity and fatty liver disease, which could complicate treatment landscapes.
- Medivir AB (OSTO:MVIR) faces uncertainty regarding the future of their oncology programs with partners like IGM Biosciences, which could impact their strategic plans.
Thank you and good afternoon. Good morning everyone to the Medivir Q3 report and we are thrilled to sort of walk you through sort of the events of the past quarter. We've seen a lot of progress in our, our lead asset FSRS and especially over the last couple of weeks. So we look forward to going through the the bigger events as we aim to bring the first oral liver targeted treatment for patients with advanced liver cancer to market.
And in terms of key events during the past quarter, as we have presented earlier in September at the ESMO Congress, we presented the mature data set from an efficacy point of view, confirming the promise of improved outcome of the combination with Fosroc and Lyve showing among other things, a 10.9 months sort of mature data set with regards to time to progression, sort of substantially longer than, than what can be expected with current treatment alternatives in second line. Sort of further strengthening our belief in the combination as a treatment option for the future P I will go through in a bit more detail sort of what we shared at SB and feedback we received from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
